ABOUT
Three promising programs. One patient-focused mission.
Neurometa Therapeutics is advancing three innovative small molecule programs designed to deliver category-leading medicines for serious neurological disorders.
By pursuing fundamental disease mechanisms through novel targets, we aim to create transformative treatments that go beyond symptom relief to truly improve the lives of those living with devastating diseases. The programs offer broad therapeutic impact and efficient development synergies.
Backed by an experienced team, Neurometa has strong momentum: securing competitive US Department of Defense funding, achieving robust results in pre-clinical disease models with excellent biomarker data, and earning acceptance into the prestigious NIH HEAL Initiative.
ORIGIN
Grounded in decades of discovery
Neurometa Therapeutics builds on decades of pioneering research in human genetics, biomarkers, advanced disease models, and quantitative systems pharmacology. This rich foundation has uncovered novel therapeutic approaches that are now being translated into promising medicines. The company bridges the groundbreaking work of original scientific innovators with expert drug developers who will guide these programs through clinical testing, ultimately delivering meaningful new treatments to patients living with serious neurological disorders.
Team
A winning combination of scientific and business experience
Preben Bruun-Nyzell
Co-Founder & CEO
Co-founder of 2A Pharma. Chair of Apoglyx. Former CFO Qatalum ($1.5bn sales, $6bn balance sheet). Prior roles at Roche, Arqaam Capital, PwC, Accenture.
Steinunn S. Helgudóttir, PhD
Co-Founder & CSO
PhD in Neuroscience, Aalborg University. 2025 Kamma Prize laureate.
John Nieland, PhD
Co-Founder & CIO
Associate Professor, Aalborg University. Former Director of Research, Medigene AG. Co-inventor of foundational Etomoxir/CPT1 work.
Anne S. Mørkholt, PhD
Co-Founder & Head of Operations
PhD Neuroscience, Aalborg University — funded by the Lundbeck Foundation.
Neil Benson, PhD
Quantitative Systems Pharmacology and PK/PD Modeling Consultant
Founder and CEO, Xenologiq and Sevenless Therapeutics. PKPD Lead, Pain at Pfizer. Former Head of Systems Pharmacology at Pfizer. Recipient of the Pfizer Upjohn Award for Innovation.
Kristina Bruun-Nyzell
Head of Business Development
Innovation strategist with 30+ years of experience supporting stakeholder engagement and partnerships.
Morten Fjordholt
Strategic Advisor, Safety Assessment
Molecular biologist and pharmaceutical toxicologist (20+ years). Board member of the Danish Toxicology & Pharmacology Society.
Fredrik Lehmann, PhD, MBA
CMC Consultant
Medicinal chemist (20+ years). Serial biotech entrepreneur. Former Venture Partner at Industrifonden, EIR Ventures, and Sound Bioventures.
Scientific Advisory Board
World-renowned KOLs in ALS and neurology
Merit Cudkowicz, MD
Scientific Advisory Board
Executive Director, Mass General Brigham Neuroscience Institute. Director, Healey & AMG Center for ALS. Professor of Neurology, Harvard Medical School.
Caroline Ingre, MD, PhD
Scientific Advisory Board
Adjunct Professor and Head of ALS Clinical Research, Karolinska Institutet, Stockholm. Board Member of TRICALS.
Claus Sundgreen, MD
Scientific Advisory Board
CMO / Medical Director with extensive ALS clinical experience. Previously VectorY, Orphazyme, TikoMed, NeuroSearch, Schering-Plough, Nycomed.
Arnar Astradsson, MD, PhD
Scientific Advisory Board
Consultant Neurosurgeon, Rigshospitalet (Copenhagen) and Harvard Medical School.